Journal
JOURNAL OF THE INDIAN INSTITUTE OF SCIENCE
Volume 102, Issue 2, Pages 671-687Publisher
SPRINGER
DOI: 10.1007/s41745-021-00268-8
Keywords
ADE; SARS-CoV-2; Neutralizing antibodies; Enhancement; ARDS; ERD
Categories
Ask authors/readers for more resources
Antibody-dependent enhancement (ADE) is a potential pathway for viral entry that could worsen infection. Variants of SARS-CoV-2 may reduce the efficacy of neutralizing antibodies, increasing the risk of severe COVID-19. Therefore, studying the effectiveness of antibodies in COVID-19 patients is crucial.
Antibody-dependent enhancement (ADE) is an alternative route of viral entry in the susceptible host cell. In this process, antiviral antibodies enhance the entry access of virus in the cells via interaction with the complement or Fc receptors leading to the worsening of infection. SARS-CoV-2 variants pose a general concern for the efficacy of neutralizing antibodies that may fail to neutralize infection, raising the possibility of a more severe form of COVID-19. Data from various studies on respiratory viruses raise the speculation that antibodies elicited against SARS-CoV-2 and during COVID-19 recovery could potentially exacerbate the infection through ADE at sub-neutralizing concentrations; this may contribute to disease pathogenesis. It is, therefore, of utmost importance to study the effectiveness of the anti-SARS-CoV-2 antibodies in COVID-19-infected subjects. Theoretically, ADE remains a general concern for the efficacy of antibodies elicited during infection, most notably in convalescent plasma therapy and in response to vaccines where it could be counterproductive.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available